Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Viridian Therapeutics (VRDN – Research Report) today and set a price ...

Thyroid eye disease (TED) therapy Tepezza – the biggest asset in Amgen's $26 billion takeover of Horizon last year – could soon face competition from a drug in the same class from Viridian ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in ...

In a report released today, Alex Thompson CFA from Stifel Nicolaus maintained a Buy rating on Oruka Therapeutics (ORKA – Research Report), with ...

A joint study conducted by UPM Raflatac and Corning Pharmaceutical Technologies has revealed the sustainability and ...

Ananda Pharma plc (AQSE: ANA), a Company focused on the development of cannabinoid-based therapies for the treatment of a range of complex conditions, today announces the appointment of Viridian ...

WALTHAM, Mass., January 08, 2025--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.